Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Ginkgo Bioworks Holdings (DNABW) Receivables - Other (2021 - 2025)

Historic Receivables - Other for Ginkgo Bioworks Holdings (DNABW) over the last 5 years, with Q3 2025 value amounting to $11.2 million.

  • Ginkgo Bioworks Holdings' Receivables - Other rose 3827.16% to $11.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.2 million, marking a year-over-year increase of 3827.16%. This contributed to the annual value of $11.3 million for FY2024, which is 1188.12% up from last year.
  • Ginkgo Bioworks Holdings' Receivables - Other amounted to $11.2 million in Q3 2025, which was up 3827.16% from $10.9 million recorded in Q2 2025.
  • Ginkgo Bioworks Holdings' 5-year Receivables - Other high stood at $11.3 million for Q4 2024, and its period low was $300000.0 during Q2 2021.
  • In the last 5 years, Ginkgo Bioworks Holdings' Receivables - Other had a median value of $10.1 million in 2023 and averaged $8.2 million.
  • As far as peak fluctuations go, Ginkgo Bioworks Holdings' Receivables - Other soared by 206666.67% in 2022, and later surged by 92.59% in 2025.
  • Ginkgo Bioworks Holdings' Receivables - Other (Quarter) stood at $4.6 million in 2021, then surged by 41.37% to $6.5 million in 2022, then surged by 55.38% to $10.1 million in 2023, then increased by 11.88% to $11.3 million in 2024, then dropped by 0.88% to $11.2 million in 2025.
  • Its Receivables - Other stands at $11.2 million for Q3 2025, versus $10.9 million for Q2 2025 and $11.3 million for Q4 2024.